the site for the Scleroderma Foundation, and articles about scleroderma in women's magazines. This only adds to her confusion and worry.

UK: A recent systematic review published in Clinical Rheumatology has investigated the potential of botulinum toxin (BTX) as ...

Explore new findings on frailty in systemic sclerosis, revealing its prevalence, dynamic progression, and impact on patient ...

From simple lifestyle changes to dietary adjustments, here are eight natural methods to help boost your circulation.

Treatment of scleroderma still faces many challenges ... to establish standardized systems for exosome preparation and quality control, laying the foundation for advancing the clinical application of ...

Gastroparesis may be acute (short-term) or chronic (long-term) and caused by many different things including diabetes, chemotherapy, and disorders like scleroderma or ... The International Foundation ...

The signs and symptoms of scleroderma can be mistaken for any number of diseases, depending on the predominant symptom at the time of examination. Numerous referrals to specialists result in ...

Professor Christopher Denton discusses key aspects of the 2024 British Society for Rheumatology guideline on managing systemic sclerosis.

Anifrolumab is under clinical development by AstraZeneca and currently in Phase III for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase III drugs for Systemic Sclerosis (Scleroderma) ...

The system was tested by (1) determining specificity and sensitivity in SSc cases and controls with scleroderma-like disorders, and (2) validating against the combined view of a group of experts on a ...

Linear scleroderma “en coup de sabre” (LScs) is associated with neurological complications, the pathogenesis of which is uncertain. A 27 year old woman is reported on who developed epilepsy and focal ...

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase II drugs for Systemic Sclerosis ...